News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRANSGENE (TRGNY) Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer



5/21/2013 10:53:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced completion of enrollment in the 120-patient TRAVERSE study. This study is a global randomized phase 2b clinical trial evaluating the efficacy and safety of Pexa-Vec (JX-594/TG6006, pexastimogene devacirepvec) for the treatment of advanced primary liver cancer (hepatocellular carcinoma, HCC) in patients who failed prior therapy with sorafenib (Nexavar®). Pexa-Vec is an investigational oncolytic immunotherapy designed to 1) rapidly de-bulk tumors via tumor cell lysis, 2) induce a durable immune response against tumors, and 3) selectively target tumor vasculature resulting in a rapid reduction in tumor blood flow.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES